z-logo
open-access-imgOpen Access
SRF-miR-29b-MMP2 axis inhibits NSCLC invasion and metastasis
Author(s) -
Hongyan Wang,
YongSheng Tu,
Jie Long,
Hui-Qiu Zhang,
Cuiling Qi,
Xiaobin Xie,
Shuhua Li,
Yajie Zhang
Publication year - 2015
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2015.3034
Subject(s) - mmp2 , metastasis , oncogene , cancer research , microrna , biology , downregulation and upregulation , cell cycle , metastasis suppressor , cell migration , cancer , cell , medicine , oncology , biochemistry , genetics , gene
MicroRNAs play key roles in tumour metastasis. miR‑29b was previously reported to act as a tumour suppressor or an oncogene in diverse cancers. However, its accurate function and mechanism in metastasis of no-small cell lung cancer (NSCLC) are not well known. In this study, we describe the function of miR‑29b in NSCLC metastasis and its regulatory mechanisms. We found that miR‑29b is downregulated in high-metastatic NSCLC cells and low-expression of miR‑29b in primary NSCLC tissue was correlated with lymph node metastasis. Both gain- and loss-of-function study indicated overexpression of miR‑29b could suppress migration and invasion abilities of high-metastatic NSCLC cells, while downregulation of miR‑29b expression promoted migration and invasion of low-metastatic NSCLC cells in vitro. Moreover, introduction of miR‑29b inhibited high‑metastatic NSCLC cells, in vivo, metastasis to liver and lungs. Mechanistically, miR‑29b, induced by the transcription factor SRF, posttranscriptionally downregulates MMP2 expression by directly targeting its 3'-untranslated regions. These findings indicate a new regulatory mode, whereby miR‑29b, which is inhibited by its upstream transcription factor SRF, was able to promote its direct target MMP2 leading to NSCLC invasion and metastasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here